Researchers at Cincinnati Children’s outlined two workflows for detecting new targets for cancer immunotherapies, one based on T cell antigens, the other upon B cell antigens. Credit: Cincinnati Children’s
An innovative computational tool dubbed “SNAF” may help the research world bring the emerging promise of cancer immunotherapy to a wider range of patients, according to a study published in Science Translational Medicine.
The research tool, called the Splicing Neo Antigen Finder (SNAF), was developed by a multidisciplinary team of researchers from Cincinnati Children’s and the University of Virginia. The project was led by Guangyuan Li, Ph.D., and Nathan Salomonis, Ph.D., both with the Division of Biomedical Informatics at Cincinnati Children’s.
The co-authors say the tool has already helped uncover shared immunogenic targets across various cancers, which could pave the way for a new wave of highly focused cancer treatments.
“The implications of this discovery are significant,” says H. Leighton “Lee” Grimes, Ph.D., a co-author of the study and director of the Cancer Pathology Program at Cincinnati Children’s. “By identifying shared splicing neoantigens present in up to 90% of cancer patients, SNAF not only presents new targets for therapy but also challenges and expands our understanding of cancer biology.”
How the new tool finds new targets
Immunotherapy, which harnesses a patient’s immune system to fight cancer, often targets neoantigens produced from genetic mutations. However, this approach typically benefits only those with a high mutational burden. SNAF aims to expand the universe of immunotherapy by identifying neoantigens arising from post-transcriptional modifications, particularly splicing errors, which have been largely untapped until now.
Using new artificial intelligence approaches, SNAF predicts immunogenic peptides that T cells can recognize and novel proteins with altered extracellular components that B cells can target. This dual approach is vital in developing comprehensive immunotherapies that engage both arms of the adaptive immune system.
Promising target emerges for melanoma
While cataloging all possible neoantigens produced from alternative mRNA pathways, the team found that the amount of splicing neoantigens is correlated with patient survival and responses to immunotherapy in patients with melanoma.
One such prediction, SLC45A2, has emerged as a particularly promising target due to its high tumor specificity and immunogenicity.
In addition to T-cell neoantigens, the team has discovered a novel class of tumor-specific extracellular neo-epitopes, termed ExNeoEpitopes, through their B-cell focused pipeline, SNAF-B. These ExNeoEpitopes show great promise for the development of monoclonal antibodies and CAR-T cell therapies.
“This is only the beginning,” says Tamara Tilburgs, Ph.D., co-corresponding author and a researcher in the Division of Immunobiology. “The SNAF workflow’s flexibility means it can be continuously adapted as we make further inroads into understanding and combating cancer.”
Salomonis and his team are now applying these tools in the most difficult-to-treat cancers to find the best targets for therapy development and understand their single-cell origins.
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost. A 2019 study estimated that orphan drug...
SN Bioscience's pioneering nanoparticle anticancer drug, SNB-101, has sparked hope for patients battling various forms of cancer. Developed from the highly insoluble SN-38 into polymer nanoparticles, SNB-101 has exhibited significant improvements in efficacy and...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD,...
The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...